| Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial A Bastidas, J De La Serna, M El Idrissi, L Oostvogels, P Quittet, ... Jama 322 (2), 123-133, 2019 | 200 | 2019 |
| Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma L Rosiñol, A Oriol, R Rios, A Sureda, MJ Blanchard, MT Hernández, ... Blood, The Journal of the American Society of Hematology 134 (16), 1337-1345, 2019 | 188 | 2019 |
| Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group) R Garcia-Sanz, A Sureda, F de la Cruz, M Canales, AP Gonzalez, ... Annals of Oncology 30 (4), 612-620, 2019 | 111 | 2019 |
| Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia AP Gonzalez-Rodriguez, J Contesti, L Huergo-Zapico, A Lopez-Soto, ... Leukemia & lymphoma 51 (10), 1829-1836, 2010 | 108 | 2010 |
| Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive disease L Huergo-Zapico, A Acebes-Huerta, AP Gonzalez-Rodriguez, J Contesti, ... PloS one 9 (10), e108326, 2014 | 103 | 2014 |
| NK cell-based immunotherapy in cancer metastasis S Lorenzo-Herrero, A López-Soto, C Sordo-Bahamonde, ... Cancers 11 (1), 29, 2018 | 101 | 2018 |
| Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells A Acebes-Huerta, L Huergo-Zapico, AP Gonzalez-Rodriguez, ... BioMed research international 2014, 2014 | 80 | 2014 |
| Molecular bases for the regulation of NKG2D ligands in cancer L Huergo-Zapico, A Acebes-Huerta, A López-Soto, M Villa-Álvarez, ... Frontiers in immunology 5, 106, 2014 | 74 | 2014 |
| Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: association with soluble MICA shedding L Huergo-Zapico, AP Gonzalez-Rodriguez, J Contesti, E Gonzalez, ... Cancer Immunology, Immunotherapy 61, 1201-1210, 2012 | 70 | 2012 |
| Conceptual aspects of self and nonself discrimination S Gonzalez, AP González-Rodríguez, A López-Soto, L Huergo-Zapico, ... Self/nonself 2 (1), 19-25, 2011 | 70 | 2011 |
| LAG-3 blockade with relatlimab (BMS-986016) restores anti-leukemic responses in chronic lymphocytic leukemia C Sordo-Bahamonde, S Lorenzo-Herrero, AP González-Rodríguez, ... Cancers 13 (9), 2112, 2021 | 66 | 2021 |
| Brentuximab vedotin plus ESHAP (BRESHAP) is a highly effective combination for inducing remission in refractory and relapsed Hodgkin lymphoma patients prior to autologous stem … R Garcia-Sanz, A Sureda, AP Gonzalez, F De la Cruz, ... Blood 128 (22), 1109, 2016 | 56 | 2016 |
| NK cells in the treatment of hematological malignancies AP Gonzalez-Rodriguez, M Villa-Álvarez, C Sordo-Bahamonde, ... Journal of clinical medicine 8 (10), 1557, 2019 | 54 | 2019 |
| Ig-like transcript 2 (ILT2) blockade and lenalidomide restore NK cell function in chronic lymphocytic leukemia M Villa-Álvarez, C Sordo-Bahamonde, S Lorenzo-Herrero, ... Frontiers in Immunology 9, 2917, 2018 | 44 | 2018 |
| Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with … MV Mateos, J Martinez-Lopez, PR Otero, V Gonzalez-Calle, MS Gonzalez, ... Blood 134, 781, 2019 | 43 | 2019 |
| Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients R Fernandez-Alvarez, AP Gonzalez-Rodriguez, A Rubio-Castro, ... Leukemia & Lymphoma 57 (2), 463-466, 2016 | 36 | 2016 |
| Curative strategy for high-risk smoldering myeloma (GEM-CESAR): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and … MV Mateos, JM Lopez, P Rodriguez-Otero, EM Ocio, MS Gonzalez, ... Blood 130, 402, 2017 | 33 | 2017 |
| Lenalidomide and chronic lymphocytic leukemia AP González-Rodríguez, AR Payer, A Acebes-Huerta, L Huergo-Zapico, ... BioMed research international 2013, 2013 | 32 | 2013 |
| BTLA/HVEM axis induces NK cell immunosuppression and poor outcome in chronic lymphocytic leukemia C Sordo-Bahamonde, S Lorenzo-Herrero, AP Gonzalez-Rodriguez, ... Cancers 13 (8), 1766, 2021 | 29 | 2021 |
| Evaluation of the regimen brentuximab vedotin plus ESHAP (BRESHAP) in refractory or relapsed Hodgkin lymphoma patients: preliminary results of a phase I-II trial from the … R Garcia-Sanz, A Sureda, S Alonso-Alvarez, AP Gonzalez, A Rodriguez, ... Blood 126 (23), 582, 2015 | 28 | 2015 |
GARCIA-SANZ RAMÓNMédicoVerified email at usal.es
